Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Details) - USD ($)	3 Months Ended
Segment Information (Details) - USD ($)	Nov. 30, 2022	Nov. 30, 2021	Aug. 31, 2022
Revenue	$ 101,476	$ 13,880
Cost of goods sold	15,795	5,570
Operating expense	(1,854,987)	(2,011,792)
Segment income (loss)	(1,769,306)	(2,003,482)
Total assets	6,213,480	11,745,942	$ 7,833,927
Products
Revenue		7,000
Cost of goods sold		5,570
Operating expense		(77,002)
Total assets		116,060
Segment loss		(75,572)
IP Licensing
Revenue	63,435	0
Cost of goods sold	0	0
Operating expense	(707,034)	(837,750)
Segment income (loss)	(643,599)	(837,750)
Total assets	118,096	724,665
Corporate
Revenue	8,941	6,880
Cost of goods sold	0	0
Operating expense	(1,136,961)	(1,097,040)
Segment income (loss)	(1,128,020)	(1,090,160)
Total assets	6,019,661	$ 10,905,217
B2B [Member]
Revenue	29,100
Cost of goods sold	15,795
Operating expense	(10,992)
Segment income (loss)	2,313
Total assets	$ 75,723